FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2278528053> ?p ?o ?g. }

• W2278528053 endingPage "72" @default.
• W2278528053 startingPage "67" @default.
• W2278528053 abstract "The efficacy of sarolaner (Simparica™, Zoetis) to prevent transmission primarily of Borrelia burgdorferi and secondarily of Anaplasma phagocytophilum from infected wild-caught Ixodes scapularis to dogs was evaluated in a placebo-controlled laboratory study. Twenty-four purpose-bred laboratory Beagles seronegative for B. burgdorferi and A. phagocytophilum antibodies were allocated randomly to one of three treatment groups: placebo administered orally on Days 0 and 7, or sarolaner at 2 mg/kg administered orally on Day 0 (28 days prior to tick infestation) or on Day 7 (21 days prior to tick infestation). On Day 28, each dog was infested with approximately 25 female and 25 male wild caught adult I. scapularis that were determined to have prevalence of 57% for B. burgdorferi and 6.7% for A. phagocytophilum by PCR. In situ tick counts were conducted on Days 29 and 30. On Day 33, all ticks were counted and removed. Acaricidal efficacy was calculated based on the reduction of geometric mean live tick counts in the sarolaner-treated groups compared to the placebo-treated group for each tick count. Blood samples collected from each dog on Days 27, 49, 63, 77, 91 and 104 were tested for the presence of B. burgdorferi and A. phagocytophilum antibodies using the SNAP® 4Dx® Plus Test, and quantitatively assayed for B. burgdorferi antibodies using an ELISA test. Skin biopsies collected on Day 104 were tested for the presence of B. burgdorferi by bacterial culture and PCR. Geometric mean live tick counts for placebo-treated dogs were 14.8, 12.8, and 19.1 on Days 29, 30, and 33, respectively. The percent reductions in mean live tick counts at 1, 2, and 5 days after infestation were 86.3%, 100%, and 100% for the group treated with sarolaner 21 days prior to infestation, and 90.9%, 97.1%, and 100% for the group treated with sarolaner 28 days prior to infestation. Geometric mean live tick counts for both sarolaner-treated groups were significantly lower than those for the placebo group on all count days (P < 0.0001). There were no adverse reactions to treatment with sarolaner. Transmission of B. burgdorferi to all eight placebo-treated dogs was confirmed by positive antibody (6 of 8 dogs), PCR (7 of 8 dogs), and/or culture (7 of 8 dogs). Similarly, transmission of A. phagocytophilum was confirmed by the presence of antibodies in four placebo-treated dogs. In contrast, treatment with a single dose of sarolaner prevented transmission of B. burgdorferi from infected ticks to dogs infested 21 or 28 days after treatment as demonstrated by negative antibody, PCR, and culture results. Prevention of transmission of A. phagocytophilum was demonstrated by negative antibody results in all sarolaner-treated dogs." @default.
• W2278528053 created "2016-06-24" @default.
• W2278528053 creator A5016342051 @default.
• W2278528053 creator A5033224530 @default.
• W2278528053 creator A5053715070 @default.
• W2278528053 creator A5076160096 @default.
• W2278528053 creator A5079589829 @default.
• W2278528053 creator A5079641649 @default.
• W2278528053 date "2016-05-01" @default.
• W2278528053 modified "2023-09-26" @default.
• W2278528053 title "Efficacy of sarolaner in the prevention of Borrelia burgdorferi and Anaplasma phagocytophilum transmission from infected Ixodes scapularis to dogs" @default.
• W2278528053 cites W1976152447 @default.
• W2278528053 cites W2001549526 @default.
• W2278528053 cites W2003678597 @default.
• W2278528053 cites W2011819409 @default.
• W2278528053 cites W2053230255 @default.
• W2278528053 cites W2071557622 @default.
• W2278528053 cites W2074419261 @default.
• W2278528053 cites W2090102364 @default.
• W2278528053 cites W2121386707 @default.
• W2278528053 cites W2141676247 @default.
• W2278528053 cites W2142982675 @default.
• W2278528053 cites W2146583652 @default.
• W2278528053 cites W2258615676 @default.
• W2278528053 cites W2286412702 @default.
• W2278528053 cites W2287234550 @default.
• W2278528053 cites W2313788533 @default.
• W2278528053 cites W2315628439 @default.
• W2278528053 cites W4244525744 @default.
• W2278528053 cites W4297596681 @default.
• W2278528053 doi "https://doi.org/10.1016/j.vetpar.2016.02.010" @default.
• W2278528053 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26906926" @default.
• W2278528053 hasPublicationYear "2016" @default.
• W2278528053 type Work @default.
• W2278528053 sameAs 2278528053 @default.
• W2278528053 citedByCount "27" @default.
• W2278528053 countsByYear W22785280532016 @default.
• W2278528053 countsByYear W22785280532017 @default.
• W2278528053 countsByYear W22785280532018 @default.
• W2278528053 countsByYear W22785280532019 @default.
• W2278528053 countsByYear W22785280532020 @default.
• W2278528053 countsByYear W22785280532021 @default.
• W2278528053 countsByYear W22785280532022 @default.
• W2278528053 crossrefType "journal-article" @default.
• W2278528053 hasAuthorship W2278528053A5016342051 @default.
• W2278528053 hasAuthorship W2278528053A5033224530 @default.
• W2278528053 hasAuthorship W2278528053A5053715070 @default.
• W2278528053 hasAuthorship W2278528053A5076160096 @default.
• W2278528053 hasAuthorship W2278528053A5079589829 @default.
• W2278528053 hasAuthorship W2278528053A5079641649 @default.
• W2278528053 hasBestOaLocation W22785280531 @default.
• W2278528053 hasConcept C142724271 @default.
• W2278528053 hasConcept C159047783 @default.
• W2278528053 hasConcept C159654299 @default.
• W2278528053 hasConcept C203014093 @default.
• W2278528053 hasConcept C204787440 @default.
• W2278528053 hasConcept C27081682 @default.
• W2278528053 hasConcept C2776370125 @default.
• W2278528053 hasConcept C2779159148 @default.
• W2278528053 hasConcept C2779620486 @default.
• W2278528053 hasConcept C2779780077 @default.
• W2278528053 hasConcept C2781453105 @default.
• W2278528053 hasConcept C42972112 @default.
• W2278528053 hasConcept C71924100 @default.
• W2278528053 hasConcept C86803240 @default.
• W2278528053 hasConcept C89423630 @default.
• W2278528053 hasConceptScore W2278528053C142724271 @default.
• W2278528053 hasConceptScore W2278528053C159047783 @default.
• W2278528053 hasConceptScore W2278528053C159654299 @default.
• W2278528053 hasConceptScore W2278528053C203014093 @default.
• W2278528053 hasConceptScore W2278528053C204787440 @default.
• W2278528053 hasConceptScore W2278528053C27081682 @default.
• W2278528053 hasConceptScore W2278528053C2776370125 @default.
• W2278528053 hasConceptScore W2278528053C2779159148 @default.
• W2278528053 hasConceptScore W2278528053C2779620486 @default.
• W2278528053 hasConceptScore W2278528053C2779780077 @default.
• W2278528053 hasConceptScore W2278528053C2781453105 @default.
• W2278528053 hasConceptScore W2278528053C42972112 @default.
• W2278528053 hasConceptScore W2278528053C71924100 @default.
• W2278528053 hasConceptScore W2278528053C86803240 @default.
• W2278528053 hasConceptScore W2278528053C89423630 @default.
• W2278528053 hasLocation W22785280531 @default.
• W2278528053 hasLocation W22785280532 @default.
• W2278528053 hasOpenAccess W2278528053 @default.
• W2278528053 hasPrimaryLocation W22785280531 @default.
• W2278528053 hasRelatedWork W1970336275 @default.
• W2278528053 hasRelatedWork W1994628611 @default.
• W2278528053 hasRelatedWork W2086444658 @default.
• W2278528053 hasRelatedWork W2101477110 @default.
• W2278528053 hasRelatedWork W2170344204 @default.
• W2278528053 hasRelatedWork W2278528053 @default.
• W2278528053 hasRelatedWork W3162412060 @default.
• W2278528053 hasRelatedWork W3177127007 @default.
• W2278528053 hasRelatedWork W3186567851 @default.
• W2278528053 hasRelatedWork W4292373072 @default.
• W2278528053 hasVolume "222" @default.
• W2278528053 isParatext "false" @default.
• W2278528053 isRetracted "false" @default.

• next